{"id":272,"date":"2026-02-17T00:23:48","date_gmt":"2026-02-17T00:23:48","guid":{"rendered":"https:\/\/discover-recovery-1-14088c5.ingress-daribow.ewp.live\/cocaine-use-reduction-with-buprenorphine\/"},"modified":"2026-02-17T00:23:48","modified_gmt":"2026-02-17T00:23:48","slug":"cocaine-use-reduction-with-buprenorphine","status":"publish","type":"post","link":"https:\/\/discover-recovery-1410e39.ingress-florina.ewp.live\/?p=272","title":{"rendered":"Can Buprenorphine Help Reduce Cocaine Use?"},"content":{"rendered":"

No FDA-approved medication currently exists to treat cocaine use disorder<\/a> \u2014 making it one of the most challenging addictions to address with pharmacotherapy. Researchers have been searching for decades, and one of the most studied candidates is <\/span>buprenorphine\/naloxone (brand name Suboxone), a combination medication already established for treating opioid use disorder.<\/span><\/p>\n

The results are nuanced. A major clinical trial called CURB (Cocaine Use Reduction with Buprenorphine) found modest but meaningful signals \u2014 particularly for people who are dealing with both cocaine and opioid use disorders at the same time. Here’s what the research actually shows, who it may apply to, and what treatment options exist today.<\/span><\/p>\n

Why Treating Cocaine Addiction Is So Difficult<\/b><\/h2>\n

No FDA-Approved Medications Exist for Cocaine Use Disorder<\/b><\/h3>\n

Unlike opioid use disorder<\/a> (treated with methadone, buprenorphine, or naltrexone) and alcohol use disorder (treated with naltrexone, acamprosate, or disulfiram), cocaine use disorder has no FDA-approved pharmacotherapy as of 2025.<\/span><\/p>\n

This gap is significant. According to SAMHSA’s 2022 National Survey<\/a> on Drug Use and Health, approximately 5.3 million Americans aged 12 or older reported past-year cocaine use \u2014 and cocaine-involved overdose deaths have increased sharply in recent years, often driven by fentanyl contamination of the cocaine supply.<\/span><\/p>\n

Cocaine and the Brain: The Dopamine Challenge<\/b><\/h3>\n

Cocaine produces its intense euphoric effects primarily by flooding the brain with dopamine \u2014 a neurotransmitter that regulates pleasure, reward, and motivation. This dopamine surge is responsible for both the high and the powerful compulsion to use again.<\/span><\/p>\n

Unlike opioids, which act on specific mu-opioid receptors that can be targeted by medications like buprenorphine in a more direct way, cocaine’s mechanism of action is broader and harder to pharmacologically counteract. Researchers have explored serotonin, GABA, norepinephrine, and the kappa-opioid system as potential targets \u2014 the last of which has led to interest in buprenorphine.<\/span><\/p>\n

What Is Buprenorphine \u2014 and Why Are Researchers Testing It for Cocaine?<\/b><\/h2>\n

How Buprenorphine Works<\/b><\/h3>\n

Buprenorphine is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist. It is FDA-approved for treating opioid use disorder and moderate-to-severe pain. When combined with naloxone (as Suboxone), it helps prevent opioid withdrawal and reduces cravings without producing the intense euphoria of full opioid agonists.<\/span><\/p>\n

Its Schedule III classification<\/a> reflects its moderate-to-low physical dependence potential compared to full opioids like methadone or heroin.<\/span><\/p>\n

The Kappa-Opioid Connection to Cocaine Craving<\/b><\/h3>\n

The scientific rationale for testing buprenorphine against cocaine centers on the kappa-opioid receptor system. Researchers theorize that the negative emotional states experienced during cocaine withdrawal \u2014 anxiety,<\/a> dysphoria, anhedonia \u2014 are driven in part by heightened kappa-opioid activity in the brain.<\/span><\/p>\n

Because buprenorphine blocks kappa-opioid receptors, the hypothesis is that it could reduce the compulsive craving driven by withdrawal distress. A landmark 1989 study by Mello and Mendelson, published in Science, found that buprenorphine suppressed cocaine self-administration in rhesus monkeys \u2014 and follow-up research<\/a> confirmed the effect held across treatment periods up to 120 days.<\/span><\/p>\n

When buprenorphine is combined with naltrexone, naltrexone blocks the mu-opioid receptor stimulation from buprenorphine \u2014 theoretically allowing researchers to selectively harness the kappa-antagonist effect without introducing opioid dependence risk.<\/span><\/p>\n

The CURB Trial: What the Research Actually Found<\/b><\/h2>\n

Key Context: The CURB trial only enrolled participants with both cocaine use disorder AND a current or past opioid use disorder. The findings do not necessarily apply to people who use cocaine without any opioid involvement.<\/b><\/p>\n

Study Design<\/b><\/h3>\n

The CURB (Cocaine Use Reduction with Buprenorphine) trial was conducted by NIDA’s Clinical Trials Network<\/a> and published in the journal Addiction in 2016. It was a multi-site, double-blind, placebo-controlled study enrolling 302 participants across 11 U.S. sites.<\/span><\/p>\n

Participants were required to meet DSM-IV criteria for cocaine dependence AND have a current or past opioid use disorder. All participants first received an extended-release naltrexone injection (Vivitrol, 380mg) before being randomized into one of three groups for 8 weeks of treatment:<\/span><\/p>\n